Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-squamous non-small cell lung cancer.
- Your cancer has stopped responding to a third-generation EGFR targeted therapy (like osimertinib).
- You must have an EGFR mutation (19 deletion or L858R) confirmed by tissue or blood test.
- You are not eligible if your cancer has transformed into small cell lung cancer or if you have certain other targetable mutations (like HER2, MET, KRAS, etc.).
- You must be able to swallow pills and have adequate organ function (kidney, liver, blood counts).
- You have not had prior treatment with pemetrexed and platinum chemotherapy for your lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
This study tests a new targeted pill (befotertinib) combined with chemotherapy for people with advanced EGFR-mutated non-small cell lung cancer. The treatment is adjusted based on how well the cancer responds, using a special blood test (MRD) to guide decisions.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.
Hear when a new Adjuvant Drug Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.